Forrester Announces Full Conference Agenda For Technology & Innovation Summit EMEA 2024
Forrester (Nasdaq: FORR) today announced the full conference agenda for Technology & Innovation Summit EMEA, held in London and digitally, October 9–11, 2024. While the potential of generative AI (genAI) to enhance efficiency and innovation is evident, tech leaders must strike the right balance, leveraging emerging technologies like automation and genAI to fuel innovation while also making sure to avoid stifling it. They need to understand where AI can make the most significant impact and identify the necessary resources for effective implementation.
At this year’s Technology & Innovation Summit EMEA, technology, data and analytics, and cybersecurity leaders will have insight into new research and learn best practices to achieve high-performance IT, understand the ethical, safe, and secure ways to take advantage of new technologies that are fundamental to building trust with their customers, and assess how to use AI as a catalyst for innovation and change.
Noteworthy keynotes and sessions include:
- Generative AI As A Forcing Factor For Change. In this keynote, technology leaders will learn how to maximise their investment in genAI to scale beyond a single use case.
- Unleash Your Potential With High-Performance IT. This keynote will cover how to align and adapt to changing business dynamics with high-performance IT.
- Embrace Trust, Adaptivity, And Alignment for AI Success. In this keynote, leaders will understand how to address the AI bottleneck by breaking down operational and data silos.
- A Fun (Yes, Really) Crash Course In EU AI Act Compliance. This session will reveal which initiatives and capabilities to prioritise and outline a dedicated roadmap to help tech leaders prepare for the impending EU AI Act.
- Staying Resilient In A Fluid Technology And Threat Landscape. In this keynote, cybersecurity leaders will explore how to approach AI practically, balancing risk and opportunity.
- AI, Low-Code, And The End Of Software Development As We Know It. This keynote will discuss the impact of genAI on the software development lifecycle and explore the emergence of application generation platforms infused with both predictive and generative AI.
“Tech, data, and security leaders in Europe are under tremendous pressure to deliver on AI investments,” said Pascal Matzke, Forrester VP and research director and T&I EMEA event host. “At Technology & Innovation EMEA, leaders will learn how to overcome common obstacles associated with the adoption of genAI and how leaders can effectively steer, align, and motivate their business to successfully scale their genAI initiatives.”
In-person attendees will experience facilitated discussions, consulting workshops, and special programmes, including the Women’s Leadership Programme; the Executive Leadership Exchange, an exclusive programme targeted at C-level leaders; and several diversity and inclusion sessions. Digital attendees will have access to all conference sessions and sponsors via the event platform.
Resources:
- Register to attend Forrester’s Technology & Innovation Summit EMEA 2024.
- View the full agenda and speakers for Technology & Innovation Summit EMEA 2024.
- Follow @Forrester and #ForrTech for updates.
About Forrester
Forrester (Nasdaq: FORR) is one of the most influential research and advisory firms in the world. We help leaders across technology, customer experience, digital, marketing, sales, and product functions use customer obsession to accelerate growth. Through Forrester’s proprietary research, consulting, and events, leaders from around the globe are empowered to be bold at work — to navigate change and put their customers at the centre of their leadership, strategy, and operations. Our unique insights are grounded in annual surveys of more than 700,000 consumers, business leaders, and technology leaders worldwide; rigorous and objective research methodologies, including Forrester Wave™ evaluations; and the shared wisdom of our clients. To learn more, visit Forrester.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903845085/en/
Contacts
Press contacts:
Hannah Segvich
hsegvich@forrester.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Logo Established for the “Japan Creator Support Fund” to Support the Global Success of Japan’s Next-Generation Creators and Artists30.6.2025 09:00:00 EEST | Press release
The Japan Arts Council (President: Mariko Hasegawa), with funding from the Agency for Cultural Affairs, has established the Japan Creator Support Fund to support projects nurturing Japan’s diverse creators and artists, and to support cultural facilities’ function enhancement. We are pleased to announce that the logo for the Fund has been established and that the English-language global website, which is promoting this project overseas, has been officially launched on Monday, June 30, 2025. A promotional video for international audiences is also now available on the website. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250627404244/en/ From the top left are the individual logos for the following support programs: the Creator & Artist Development Support Program [FOR CREATORS], the Support Program for Cultural Facilities Function Enhancement [FOR CULTURAL FACILITIES], the Creator Support Program (Program Development & Implem
From Waste to Strategic Metals: Circular Materials Achieves First Industrial-Scale Recoveries Under the Critical Raw Materials Act30.6.2025 09:00:00 EEST | Press release
Circular Materials announces two major milestones under the Critical Raw Materials Act: the recovery from industrial wastewater of the first kilogram of ruthenium and the first ton of nickel, preventing the release of heavy metals into the environment. These results were secured through strong collaborations with two leading companies in surface treatments: LEM, core company of the LEM INDUSTRIES Group, specialized in the luxury sector, and Argos Surface Technologies Group, a leader in industrial coatings. This success comes just a few months after the European Commission recognized Recover-IT as a strategic project, confirming the pivotal role of Circular Materials in securing critical raw material supplies, increasing recycling, and reducing the EU’s dependence on imports. Ruthenium and Nickel: crucial metals for a sustainable future Ruthenium, a noble metal from the platinum group, is essential for cutting-edge sectors such as advanced electronics, green hydrogen production, fine ch
SBC Medical added to membership of Russell 3000 ® Index28.6.2025 02:30:00 EEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250608244276/en/ Yoshiyuki Aikawa-Director (Chairman), CEO Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000®Index as well as the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to
Altimetrik and SLK Software Join Forces to Create an AI-First Engineering Services Powerhouse27.6.2025 23:44:00 EEST | Press release
Altimetrik, a pure-play AI, Data and Digital engineering solutions company, today announced the signing of a definitive agreement to acquire SLK Software (“SLK”), a global technology services firm focused on delivering AI, intelligence automation and analytics solutions. The acquisition will further strengthen Altimetrik’s end-to-end enablement services and expand its customer reach, with a clear path to accelerate towards Altimetrik’s goal of reaching $1billion in annual revenue. The transaction remains subject to customary closing conditions and is expected to close in the second half of 2025. Financial details were not disclosed. Founded in 2000, SLK is recognized as a leader in the tech industry, and for its commitment to create innovative digital solutions. This strategic acquisition will significantly enhance the scale of Altimetrik’s capabilities, bringing together Altimetrik’s AI-first, platform-native engineering model and SLK’s full technology services stack that will further
PRD Therapeutics Announces Initiation of First-in-Human Study for PRD00127.6.2025 17:00:00 EEST | Press release
PRD Therapeutics, Inc., a clinical stage company focused on the development of novel lipid metabolism regulators targeting homozygous familial hypercholesterolemia (HoFH) and metabolic dysfunction associated fatty liver disease (MASH/MASLD), today announced that the company recently initiated dosing in a First-in-Human (FIH) clinical trial of PRD001, a first-in-class SOAT2 (formerly known as ACAT2) selective inhibitor. “We are excited to initiate dosing in this clinical trial of PRD001. Many clinical trials have been conducted on SOAT1/2 dual or SOAT1 selective inhibitors, but this is the first clinical trial of an SOAT2 selective inhibitor” said Kanji Hosoda, Ph.D., CEO and co-founder of PRD Therapeutics. “Several results with SOAT1 or 2 knockout mice have been published, suggesting that knocking out or inhibiting only SOAT2 is crucial to demonstrate safety and efficacy. PRD001 is the world's first and only SOAT2-selective inhibitor and is expected to exhibit safety and efficacy in hu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom